{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:37:14Z","timestamp":1790289434273,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10792-021-02188-z","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:03:06Z","timestamp":1643500986000},"page":"1905-1913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-9828","authenticated-orcid":false,"given":"El\u00e7in","family":"S\u00fcren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3523-8479","authenticated-orcid":false,"given":"Dilek","family":"\u00d6zkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6876-554X","authenticated-orcid":false,"given":"Ersan","family":"\u00c7etinkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-6634","authenticated-orcid":false,"given":"Mustafa","family":"Kalayc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-7965","authenticated-orcid":false,"given":"Kenan","family":"Yi\u011fit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-7869","authenticated-orcid":false,"given":"Mehmet Fatih","family":"K\u00fcc\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-8065","authenticated-orcid":false,"given":"Muhammet Kazim","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"issue":"10","key":"2188_CR1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/nm1095-1024","volume":"1","author":"T Alon","year":"1995","unstructured":"Alon T, Hemo I, Itin A et al (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1(10):1024\u20131028","journal-title":"Nat Med"},{"issue":"2","key":"2188_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84(2):77\u201382","journal-title":"Early Hum Dev"},{"issue":"4","key":"2188_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","volume":"156","author":"K Lashkari","year":"2000","unstructured":"Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N (2000) Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 156(4):1337\u20131344","journal-title":"Am J Pathol"},{"key":"2188_CR4","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1167\/iovs.08-2584","volume":"49","author":"LEH Smith","year":"2008","unstructured":"Smith LEH (2008) Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 49:5177\u20135182","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2188_CR5","doi-asserted-by":"crossref","unstructured":"Riazi-Esfahani H, Mahmoudi A, Sanatkar M, Farahani AD, Bazvand F (2021). Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity. Int J Retina Vitreous. 13;7(1):60.","DOI":"10.1186\/s40942-021-00334-4"},{"key":"2188_CR6","doi-asserted-by":"crossref","unstructured":"Bassiouny RM, Gaafar WM, El Nokrashy A, Abdelhameed AG, Attallah EA, Elgharieb AG, Bassiouny MR. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity. Eye (Lond). 2021;28.","DOI":"10.1038\/s41433-021-01814-5"},{"key":"2188_CR7","first-page":"15","volume":"8","author":"MN Menke","year":"2015","unstructured":"Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S (2015) Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 8:15\u201320","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"2188_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3341\/kjo.2018.0011","volume":"32","author":"HG Kang","year":"2018","unstructured":"Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, Kim M (2018) Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes. Korean J Ophthalmol 32(6):451\u2013458","journal-title":"Korean J Ophthalmol"},{"issue":"6","key":"2188_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol MK, Coban DT, Sar\u0131 ES, Bilgin AB, Dogan B, Ozdemir O, Tunay ZO (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78(6):340\u2013343","journal-title":"Arq Bras Oftalmol"},{"key":"2188_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000489023","volume":"240","author":"S Kimyon","year":"2018","unstructured":"Kimyon S, Mete A (2018) Comparison of Bevacizumab and Ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1. Ophthalmologica 240:99\u2013105","journal-title":"Ophthalmologica"},{"key":"2188_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC, Wu WC (2018) Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 256:479\u2013487","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2188_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","volume":"257","author":"EA Sukgen","year":"2019","unstructured":"Sukgen EA, Ko\u00e7luk Y (2019) Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 257:49\u201355","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2188_CR13","first-page":"1","volume":"17","author":"D Cam","year":"2016","unstructured":"Cam D, Berk AT, Micili SC et al (2016) Histological and immunohistochemical retinal changes following the intravitreal injection of Aflibercept, bevacizumab, and Ranibizumab in newborn rabbits. Curr Eye Res 17:1\u20138","journal-title":"Curr Eye Res"},{"key":"2188_CR14","doi-asserted-by":"crossref","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7): 991\u20139.","DOI":"10.1001\/archopht.123.7.991"},{"key":"2188_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Opthalmol 121:1684\u20131694","journal-title":"Arch Opthalmol"},{"key":"2188_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1364\/BOE.11.000068","volume":"11","author":"D Toslak","year":"2020","unstructured":"Toslak D, Chau F, Erol MK, Liu C, Chan RVP, Son T, Yao X (2020) Trans-pars-planar illumination enables a 200\u00b0 ultra-wide field pediatric fundus camera for easy examination of the retina. Biomed Opt Express 11:68\u201376","journal-title":"Biomed Opt Express"},{"issue":"5","key":"2188_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchison AD, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of premature: a 5-year retrospective analysis. Ophthlamology 122(5):1008\u20131015","journal-title":"Ophthlamology"},{"key":"2188_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","volume":"88","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA (2012) Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev 88:937\u2013941","journal-title":"Early Hum Dev"},{"key":"2188_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155:150\u2013158","journal-title":"Am J Ophthalmol"},{"key":"2188_CR20","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z (2015) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity\u201327 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 253:1677\u20131683","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2188_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajo.2006.03.036","volume":"142","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ (2006) Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 142(1):141\u2013143","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2188_CR22","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 11(1):e0148019","journal-title":"PLoS ONE"},{"key":"2188_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Martinez-Castellanos","year":"2013","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL et al (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 33:329\u2013338","journal-title":"Retina"},{"issue":"4","key":"2188_CR24","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137(4):e20153218","journal-title":"Pediatrics"},{"issue":"3","key":"2188_CR25","doi-asserted-by":"publisher","first-page":"e0230678","DOI":"10.1371\/journal.pone.0230678","volume":"15","author":"M Arima","year":"2020","unstructured":"Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, Nakama T, Tsukamoto S, Ochiai M, Ohga S, Sonoda KH (2020) Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE 15(3):e0230678","journal-title":"PLoS ONE"},{"key":"2188_CR26","doi-asserted-by":"crossref","unstructured":"Stahl A,\u00a0Lepore D,\u00a0Fielder A,\u00a0Fleck B,\u00a0Reynolds JD,\u00a0Chiang MF et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial Lancet 2019;394:1551\u20139.","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"2188_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","volume":"148","author":"K Csaky","year":"2009","unstructured":"Csaky K, Do DV (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148:647\u2013656","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2188_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CP, Lien R, Wang NK et al (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694\u2013701","journal-title":"Retina"},{"issue":"10","key":"2188_CR29","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 37(10):1847\u20131858","journal-title":"Retina"},{"issue":"4","key":"2188_CR30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","volume":"154","author":"TU Krohne","year":"2012","unstructured":"Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154(4):682\u2013686","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2188_CR31","first-page":"641","volume":"11","author":"XM Yang","year":"2018","unstructured":"Yang XM, Zhao YX, Wang ZH, Liu L (2018) Effect of anti-VEGF treatment on retinopathy of prematurity in Zone II Stage 3+. Int J Ophthalmol 11(4):641\u2013644","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"2188_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","volume":"67","author":"V Vedantham","year":"2019","unstructured":"Vedantham V (2019) Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity. Indian J Ophthalmol 67(6):884\u2013888","journal-title":"Indian J Ophthalmol"},{"issue":"10","key":"2188_CR33","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s10792-018-1040-x","volume":"39","author":"A Vural","year":"2019","unstructured":"Vural A, Perente \u0130, Onur \u0130U, Eri\u015f E, Seymen Z, Herg\u00fcnsel GO et al (2019) Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography. Int Ophthalmol 39(10):2161\u20132169","journal-title":"Int Ophthalmol"},{"issue":"1","key":"2188_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000364809","volume":"53","author":"AG Salman","year":"2015","unstructured":"Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in highrisk prethreshold type 1 retinopathy of prematurity. Opthalmic Res 53(1):15\u201320","journal-title":"Opthalmic Res"},{"issue":"6","key":"2188_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5301\/ejo.5000938","volume":"27","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, S\u00f6ker G, Ko\u00e7luk Y, G\u00fclek B (2017) Effect of intravitreal aflibercept on central retinal arterial blood flow in type 1 retinopathy of prematurity. Eur J Ophthalmol 27(6):751\u2013755","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"2188_CR36","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","volume":"41","author":"Z Yi","year":"2016","unstructured":"Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, Chen C (2016) Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res 41(8):1092\u20131097","journal-title":"Curr Eye Res"},{"key":"2188_CR37","doi-asserted-by":"crossref","unstructured":"Geloneck MM,\u00a0Chuang AZ,\u00a0Clark WL,\u00a0Hunt MG,\u00a0Norman AA,\u00a0Packwood EA,\u00a0Tawansy KA,\u00a0Mintz-Hittner HA,\u00a0BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol\u00a02014;132(11):1327\u201333.","DOI":"10.1001\/jamaophthalmol.2014.2772"},{"issue":"12","key":"2188_CR38","doi-asserted-by":"publisher","first-page":"e0225643","DOI":"10.1371\/journal.pone.0225643","volume":"14","author":"QQ Tan","year":"2019","unstructured":"Tan QQ, Christiansen SP, Jingyun WJ (2019) Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review. PLoS ONE 14(12):e0225643","journal-title":"PLoS ONE"},{"issue":"4","key":"2188_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"SN Chen","year":"2015","unstructured":"Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, Chuang CC, Wu WC (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 35(4):667\u2013674","journal-title":"Retina"},{"key":"2188_CR40","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/OPTH.S110717","volume":"10","author":"CJ Lin","year":"2016","unstructured":"Lin CJ, Tsai YY (2016) Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. Clin Ophthalmol 10:1323\u20131327","journal-title":"Clin Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02188-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02188-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02188-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T13:16:58Z","timestamp":1654003018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02188-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2188"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02188-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"14 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}